Sara Abbasian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sara Abbasian has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Farshad Gharebakhshi
Department of Radiology, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Elahe Zaremoghadam
Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
2 shared publications - Soleyman Alivand
Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications - Ali Asadian
Department of Anesthesiology, School of Paramedical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Ali Khodaparast
Department of Nephrology, Hasheminejad Kidney Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Anahita Kalirad
Department of Radiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 4 December 2023
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 9 (1) , e35232
How lifestyle factors can contribute to cardiovascular disease incidence; a review study
Cardiovascular diseases (CVDs) are a group of diseases that include cardiac and blood vessels. Lifestyle factors for cardiovascular diseases refer to the behaviors and habits that can enhance or reduce the risk of developing heart disease. In this review study, we did a comprehensive search in the online database, including PubMed, Web of Science, Scopus, and motor search engines such as Google Scholar. We investigated the studies that assessed lifestyle factors for CVD incidence. Results showed that physical inactivity, unhealthy diet, alcohol consumption, smoking, obesity, and stress are the most common lifestyle factors related to the incidence of CVDs.
- 4 December 2023
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 9 (1) , e35232
Open AccessHow lifestyle factors can contribute to cardiovascular disease incidence; a review study
Cardiovascular diseases (CVDs) are a group of diseases that include cardiac and blood vessels. Lifestyle factors for cardiovascular diseases refer to the behaviors and habits that can enhance or reduce the risk of developing heart disease. In this review study, we did a comprehensive search in the online database, including PubMed, Web of Science, Scopus, and motor search engines such as Google Scholar. We investigated the studies that assessed lifestyle factors for CVD incidence. Results showed that physical inactivity, unhealthy diet, alcohol consumption, smoking, obesity, and stress are the most common lifestyle factors related to the incidence of CVDs.
- Open Access
- 27 November 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (1) , e11651
The association between metformin administration and non-Hodgkin lymphoma; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Metformin, a blood sugar-lowering agent, has the potential to be an anti-cancer agent. However, its role in lymphoma remains uncertain. Objectives: This study sought to examine the correlation between the utilization of metformin and non-Hodgkin lymphoma through the application of a systematic review and meta-analysis methodology. Materials and Methods: This investigation was carried out in the form of a methodical examination and meta-analysis in accordance with the PRISMA guidelines. Databases such as Scopus, PubMed, Web of Science, Cochrane, and the Google Scholar search engine were thoroughly explored without any temporal limitations until September 20, 2023. The data was analyzed utilizing the STATA 14 software, and the level of significance for the tests was established at P<0.05. Results: The results, obtained by combining six observational studies (five cohort studies and one case-control study) with a total sample size of 2 330 787 individuals, showed that the odds ratio (OR) for the association between metformin use and non-Hodgkin lymphoma in all studies was 0.91 (95% CI: 0.78, 1.07). In cohort studies, the OR was 0.91 (95% CI: 0.74, 1.11), and in the case-control study, it was 0.93 (95% CI: 0.79, 1.10). None of these relationships were statistically significant. The odds ratio between metformin uses and chronic lymphocytic leukemia/small lymphocytic leukemia was 0.93 (95% CI: 0.71, 1.21), and the odds ratio between metformin use and diffuse large B-cell lymphoma was 1.06 (95% CI: 0.61, 1.83), both of which were not statistically significant. Conclusion: This investigation’s findings indicated no statistically noteworthy correlation exists between the utilization of metformin and the probability of contracting non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic leukemia, and diffuse large B-cell lymphoma. Registration: This study was conducted following the PRISMA checklist. Its protocol was registered on the PROSPERO (CRD42023469100) and Research Registry (UIN: reviewregistry1721) websites.
- 27 November 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropharmacology
- Vol. 13 (1) , e11651
Open AccessThe association between metformin administration and non-Hodgkin lymphoma; a systematic review and meta-analysis of cohort and case-control studies
Introduction: Metformin, a blood sugar-lowering agent, has the potential to be an anti-cancer agent. However, its role in lymphoma remains uncertain. Objectives: This study sought to examine the correlation between the utilization of metformin and non-Hodgkin lymphoma through the application of a systematic review and meta-analysis methodology. Materials and Methods: This investigation was carried out in the form of a methodical examination and meta-analysis in accordance with the PRISMA guidelines. Databases such as Scopus, PubMed, Web of Science, Cochrane, and the Google Scholar search engine were thoroughly explored without any temporal limitations until September 20, 2023. The data was analyzed utilizing the STATA 14 software, and the level of significance for the tests was established at P<0.05. Results: The results, obtained by combining six observational studies (five cohort studies and one case-control study) with a total sample size of 2 330 787 individuals, showed that the odds ratio (OR) for the association between metformin use and non-Hodgkin lymphoma in all studies was 0.91 (95% CI: 0.78, 1.07). In cohort studies, the OR was 0.91 (95% CI: 0.74, 1.11), and in the case-control study, it was 0.93 (95% CI: 0.79, 1.10). None of these relationships were statistically significant. The odds ratio between metformin uses and chronic lymphocytic leukemia/small lymphocytic leukemia was 0.93 (95% CI: 0.71, 1.21), and the odds ratio between metformin use and diffuse large B-cell lymphoma was 1.06 (95% CI: 0.61, 1.83), both of which were not statistically significant. Conclusion: This investigation’s findings indicated no statistically noteworthy correlation exists between the utilization of metformin and the probability of contracting non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic leukemia, and diffuse large B-cell lymphoma. Registration: This study was conducted following the PRISMA checklist. Its protocol was registered on the PROSPERO (CRD42023469100) and Research Registry (UIN: reviewregistry1721) websites.
- Open Access
- 31 August 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 12 (4) , e32207
The effect of cinacalcet on hypercalcemia in kidney transplant patients with hyperparathyroidism: systematic review and meta-analysis
Introduction: Following renal transplantation, patients with end-stage renal disease develop parathyroid dysfunction and electrolyte abnormalities, including calcium and phosphate levels. However, cinacalcet is one of the most used medications for hypercalcemia. Therefore, the present systematic review and meta-analysis aimed to investigate the effect of cinacalcet administration on hypercalcemia in patients with renal transplantation. Materials and Methods: The online databases of Cochrane, Web of Science, Scopus, and PubMed were searched until April 2023 using validated keywords. Moreover, PRISMA was used for qualitatively evaluating the studies since the study protocol was registered on the PROSPERO website. In addition, data analysis was conducted using Stata version 14, and the significance level was set at 0.05. Results: The present meta-analysis included 26 studies (24 cohort studies and two randomized clinical trials) investigating 602 patients with renal transplantation and hyperparathyroidism. According to our findings, cinacalcet reduced the serum calcium (MD: -2.24, 95% CI: -2.82, -1.67), parathormone (SMD: -0.85, 95% CI: -1.15, -0.54), and alkaline phosphatase levels (SMD: -0.45, 95% CI: -0.91, -0.01). Moreover, 30-60 mg of cinacalcet per day effectively treated hypercalcemia (SMD: -2.77, 95% CI: -3.57, -1.98), while other doses were not significantly effective. Furthermore, the effect of cinacalcet was investigated in patients using the medication for less than six months (SMD: -2.55, 95% CI: -4.25, -0.86), 12-18 months (SMD: -2.60, 95% CI: -3.53, -1.67), and more than 24 months (SMD: -1.71, 95% CI: -2.54, -0.88). Finally, the effect of cinacalcet was the highest in the patients who were 60-64 years old compared to other age groups (SMD: -3.59, 95% CI: -5.14, -2.04). Conclusion: Cinacalcet could improve hypercalcemia and hyperparathyroidism in patients with renal transplantation. Moreover, the effect of cinacalcet had a direct and positive relationship with the patient’s age. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42023428620) and Research Registry (UIN: reviewregistry1667) website.
- 31 August 2023
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 12 (4) , e32207
Open AccessThe effect of cinacalcet on hypercalcemia in kidney transplant patients with hyperparathyroidism: systematic review and meta-analysis
Introduction: Following renal transplantation, patients with end-stage renal disease develop parathyroid dysfunction and electrolyte abnormalities, including calcium and phosphate levels. However, cinacalcet is one of the most used medications for hypercalcemia. Therefore, the present systematic review and meta-analysis aimed to investigate the effect of cinacalcet administration on hypercalcemia in patients with renal transplantation. Materials and Methods: The online databases of Cochrane, Web of Science, Scopus, and PubMed were searched until April 2023 using validated keywords. Moreover, PRISMA was used for qualitatively evaluating the studies since the study protocol was registered on the PROSPERO website. In addition, data analysis was conducted using Stata version 14, and the significance level was set at 0.05. Results: The present meta-analysis included 26 studies (24 cohort studies and two randomized clinical trials) investigating 602 patients with renal transplantation and hyperparathyroidism. According to our findings, cinacalcet reduced the serum calcium (MD: -2.24, 95% CI: -2.82, -1.67), parathormone (SMD: -0.85, 95% CI: -1.15, -0.54), and alkaline phosphatase levels (SMD: -0.45, 95% CI: -0.91, -0.01). Moreover, 30-60 mg of cinacalcet per day effectively treated hypercalcemia (SMD: -2.77, 95% CI: -3.57, -1.98), while other doses were not significantly effective. Furthermore, the effect of cinacalcet was investigated in patients using the medication for less than six months (SMD: -2.55, 95% CI: -4.25, -0.86), 12-18 months (SMD: -2.60, 95% CI: -3.53, -1.67), and more than 24 months (SMD: -1.71, 95% CI: -2.54, -0.88). Finally, the effect of cinacalcet was the highest in the patients who were 60-64 years old compared to other age groups (SMD: -3.59, 95% CI: -5.14, -2.04). Conclusion: Cinacalcet could improve hypercalcemia and hyperparathyroidism in patients with renal transplantation. Moreover, the effect of cinacalcet had a direct and positive relationship with the patient’s age. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42023428620) and Research Registry (UIN: reviewregistry1667) website.
- Open Access
- 27 January 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Pulmonary radiologic findings based on Warrick score as a predictor of COVID-19 patients’ outcomes
Introduction: Predicting factors related to the severity and mortality of coronavirus disease 2019 (COVID-19) patients can significantly help in better management of their treatment. Objectives: This study aimed to investigate the correlation between pulmonary radiologic findings based on the Warrick score and COVID-19 patients’ outcomes. Patients and Methods: This descriptive-analytical study was conducted on 436 COVID-19 patients hospitalized at Shahid Mohammadi hospital in Bandar Abbas. Pulmonary radiologic findings were scored based on the Warrick score. Outcomes of COVID-19 patients, including disease severity and mortality, were followed. Independent T-test and binary logistic regression were conducted to explore the correlation between the pulmonary radiologic findings and patients’ outcomes. Results: Results showed that the correlation between pulmonary radiologic findings with both disease severity and mortality was significant, since higher pulmonary involvement caused greater severity and mortality. The Warrick score difference between dead and recovered patients and low and high disease severity were significant, therefore greater Warrick score caused more disease severity and mortality. Conclusion: Pulmonary radiologic findings based on the Warrick score can use as a predictor of COVID-19 patients’ outcomes.
- 27 January 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Open AccessPulmonary radiologic findings based on Warrick score as a predictor of COVID-19 patients’ outcomes
Introduction: Predicting factors related to the severity and mortality of coronavirus disease 2019 (COVID-19) patients can significantly help in better management of their treatment. Objectives: This study aimed to investigate the correlation between pulmonary radiologic findings based on the Warrick score and COVID-19 patients’ outcomes. Patients and Methods: This descriptive-analytical study was conducted on 436 COVID-19 patients hospitalized at Shahid Mohammadi hospital in Bandar Abbas. Pulmonary radiologic findings were scored based on the Warrick score. Outcomes of COVID-19 patients, including disease severity and mortality, were followed. Independent T-test and binary logistic regression were conducted to explore the correlation between the pulmonary radiologic findings and patients’ outcomes. Results: Results showed that the correlation between pulmonary radiologic findings with both disease severity and mortality was significant, since higher pulmonary involvement caused greater severity and mortality. The Warrick score difference between dead and recovered patients and low and high disease severity were significant, therefore greater Warrick score caused more disease severity and mortality. Conclusion: Pulmonary radiologic findings based on the Warrick score can use as a predictor of COVID-19 patients’ outcomes.
- Open Access
- 19 October 2022
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 10 (1) , e11161
Correlation of thyroid status with severity and mortality of COVID-19 patients
Introduction: Thyroid status because of the expression of angiotensin-converting enzyme-2 (ACE2), which is a functional receptor for coronavirus disease 2019 (COVID-19) in thyroid glands, maybe affects COVID-19 patients’ outcomes. Objectives: This study aimed to evaluate the correlation of thyroid status with the severity and mortality of COVID-19 patients. Patients and Methods: In a retrospective cohort study conducted on 521 COVID-19 patients, data were collected by a demographic questionnaire and a checklist of patient outcomes (death/recovery) from the hospital information system (HIS) and analyzed by SPSS version 26 and binary logistic regression. Data about thyroid status were collected from clinical documents and laboratory test data. Results: Most patients were male (57.2%) with a mean age of 56.12 ± 17.4 years. Seventy-seven patients had a severe stage of disease, and 55 patients died. Twenty-one patients had hyperthyroidism, and 53 patients had hypothyroidism. Results showed that the correlation between hypothyroidism and hyperthyroidism with severity and mortality risk of COVID-19 patients was insignificant (P > 0.05). Conclusion: In this study, we concluded that, thyroid status is not associated with COVID-19 outcomes such as severity or mortality.
- 19 October 2022
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 10 (1) , e11161
Open AccessCorrelation of thyroid status with severity and mortality of COVID-19 patients
Introduction: Thyroid status because of the expression of angiotensin-converting enzyme-2 (ACE2), which is a functional receptor for coronavirus disease 2019 (COVID-19) in thyroid glands, maybe affects COVID-19 patients’ outcomes. Objectives: This study aimed to evaluate the correlation of thyroid status with the severity and mortality of COVID-19 patients. Patients and Methods: In a retrospective cohort study conducted on 521 COVID-19 patients, data were collected by a demographic questionnaire and a checklist of patient outcomes (death/recovery) from the hospital information system (HIS) and analyzed by SPSS version 26 and binary logistic regression. Data about thyroid status were collected from clinical documents and laboratory test data. Results: Most patients were male (57.2%) with a mean age of 56.12 ± 17.4 years. Seventy-seven patients had a severe stage of disease, and 55 patients died. Twenty-one patients had hyperthyroidism, and 53 patients had hypothyroidism. Results showed that the correlation between hypothyroidism and hyperthyroidism with severity and mortality risk of COVID-19 patients was insignificant (P > 0.05). Conclusion: In this study, we concluded that, thyroid status is not associated with COVID-19 outcomes such as severity or mortality.